118 related articles for article (PubMed ID: 33252239)
1. Discovery of Potent, Highly Selective, and
Pissot Soldermann C; Simic O; Renatus M; Erbel P; Melkko S; Wartmann M; Bigaud M; Weiss A; McSheehy P; Endres R; Santos P; Blank J; Schuffenhauer A; Bold G; Buschmann N; Zoller T; Altmann E; Manley PW; Dix I; Buchdunger E; Scesa J; Quancard J; Schlapbach A; Bornancin F; Radimerski T; Régnier CH
J Med Chem; 2020 Dec; 63(23):14576-14593. PubMed ID: 33252239
[TBL] [Abstract][Full Text] [Related]
2. Optimization of the
Quancard J; Simic O; Pissot Soldermann C; Aichholz R; Blatter M; Renatus M; Erbel P; Melkko S; Endres R; Sorge M; Kieffer L; Wagner T; Beltz K; Mcsheehy P; Wartmann M; Régnier CH; Calzascia T; Radimerski T; Bigaud M; Weiss A; Bornancin F; Schlapbach A
J Med Chem; 2020 Dec; 63(23):14594-14608. PubMed ID: 33216547
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship studies of 3-substituted pyrazoles as novel allosteric inhibitors of MALT1 protease.
Asaba KN; Adachi Y; Tokumaru K; Watanabe A; Goto Y; Aoki T
Bioorg Med Chem Lett; 2021 Jun; 41():127996. PubMed ID: 33775836
[TBL] [Abstract][Full Text] [Related]
4. Discovery and optimization of cyclohexane-1,4-diamines as allosteric MALT1 inhibitors.
Schiesser S; Hajek P; Pople HE; Käck H; Öster L; Cox RJ
Eur J Med Chem; 2022 Jan; 227():113925. PubMed ID: 34742013
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.
Liang X; Sun C; Li C; Yu H; Wei X; Liu X; Bao W; Shi Y; Sun X; Khamrakulov M; Yang C; Liu H
J Med Chem; 2021 Jul; 64(13):9217-9237. PubMed ID: 34181850
[TBL] [Abstract][Full Text] [Related]
6. Discovery and optimization of a series of small-molecule allosteric inhibitors of MALT1 protease.
Lu T; Connolly PJ; Philippar U; Sun W; Cummings MD; Barbay K; Gys L; Van Nuffel L; Austin N; Bekkers M; Shen F; Cai A; Attar R; Meerpoel L; Edwards J
Bioorg Med Chem Lett; 2019 Dec; 29(23):126743. PubMed ID: 31678006
[TBL] [Abstract][Full Text] [Related]
7. N-aryl-piperidine-4-carboxamides as a novel class of potent inhibitors of MALT1 proteolytic activity.
Schlapbach A; Revesz L; Pissot Soldermann C; Zoller T; Régnier CH; Bornancin F; Radimerski T; Blank J; Schuffenhauer A; Renatus M; Erbel P; Melkko S; Heng R; Simic O; Endres R; Wartmann M; Quancard J
Bioorg Med Chem Lett; 2018 Jul; 28(12):2153-2158. PubMed ID: 29759726
[TBL] [Abstract][Full Text] [Related]
8. Peptide-based covalent inhibitors of MALT1 paracaspase.
Hatcher JM; Du G; Fontán L; Us I; Qiao Q; Chennamadhavuni S; Shao J; Wu H; Melnick A; Gray NS; Scott DA
Bioorg Med Chem Lett; 2019 Jun; 29(11):1336-1339. PubMed ID: 30954428
[TBL] [Abstract][Full Text] [Related]
9. A patent review of MALT1 inhibitors (2013-present).
Hamp I; O'Neill TJ; Plettenburg O; Krappmann D
Expert Opin Ther Pat; 2021 Dec; 31(12):1079-1096. PubMed ID: 34214002
[TBL] [Abstract][Full Text] [Related]
10. MALT1 inhibitors prevent the development of DSS-induced experimental colitis in mice via inhibiting NF-κB and NLRP3 inflammasome activation.
Liu W; Guo W; Hang N; Yang Y; Wu X; Shen Y; Cao J; Sun Y; Xu Q
Oncotarget; 2016 May; 7(21):30536-49. PubMed ID: 27105502
[TBL] [Abstract][Full Text] [Related]
11. Development of new Malt1 inhibitors and probes.
Xin BT; Schimmack G; Du Y; Florea BI; van der Marel GA; Driessen C; Krappmann D; Overkleeft HS
Bioorg Med Chem; 2016 Aug; 24(15):3312-29. PubMed ID: 27085674
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology.
Martin K; Junker U; Tritto E; Sutter E; Rubic-Schneider T; Morgan H; Niwa S; Li J; Schlapbach A; Walker D; Bigaud M; Beerli C; Littlewood-Evans A; Rudolph B; Laisney M; Ledieu D; Beltz K; Quancard J; Bornancin F; Zamurovic Ribrioux N; Calzascia T
Front Immunol; 2020; 11():745. PubMed ID: 32425939
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
[TBL] [Abstract][Full Text] [Related]
14. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.
Fontán L; Qiao Q; Hatcher JM; Casalena G; Us I; Teater M; Durant M; Du G; Xia M; Bilchuk N; Chennamadhavuni S; Palladino G; Inghirami G; Philippar U; Wu H; Scott DA; Gray NS; Melnick A
J Clin Invest; 2018 Oct; 128(10):4397-4412. PubMed ID: 30024860
[TBL] [Abstract][Full Text] [Related]
15. Targeting MALT1 Proteolytic Activity in Immunity, Inflammation and Disease: Good or Bad?
Demeyer A; Staal J; Beyaert R
Trends Mol Med; 2016 Feb; 22(2):135-150. PubMed ID: 26787500
[TBL] [Abstract][Full Text] [Related]
16. A MALT1 inhibitor suppresses human myeloid DC, effector T-cell and B-cell responses and retains Th1/regulatory T-cell homeostasis.
Dumont C; Sivars U; Andreasson T; Odqvist L; Mattsson J; DeMicco A; Pardali K; Johansson G; Yrlid L; Cox RJ; Seeliger F; Larsson M; Gehrmann U; Davis AM; Vaarala O
PLoS One; 2020; 15(9):e0222548. PubMed ID: 32870913
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Guo Y; Liu Y; Hu N; Yu D; Zhou C; Shi G; Zhang B; Wei M; Liu J; Luo L; Tang Z; Song H; Guo Y; Liu X; Su D; Zhang S; Song X; Zhou X; Hong Y; Chen S; Cheng Z; Young S; Wei Q; Wang H; Wang Q; Lv L; Wang F; Xu H; Sun H; Xing H; Li N; Zhang W; Wang Z; Liu G; Sun Z; Zhou D; Li W; Liu L; Wang L; Wang Z
J Med Chem; 2019 Sep; 62(17):7923-7940. PubMed ID: 31381333
[TBL] [Abstract][Full Text] [Related]
18. 3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
Jorda R; Havlíček L; Šturc A; Tušková D; Daumová L; Alam M; Škerlová J; Nekardová M; Peřina M; Pospíšil T; Široká J; Urbánek L; Pachl P; Řezáčová P; Strnad M; Klener P; Kryštof V
J Med Chem; 2019 May; 62(9):4606-4623. PubMed ID: 30943029
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of MALT1 protease activity suppresses endothelial activation via enhancing MCPIP1 expression.
Li Y; Huang S; Huang X; Li X; Falcon A; Soutar A; Bornancin F; Jiang Z; Xin HB; Fu M
Cell Signal; 2018 Oct; 50():1-8. PubMed ID: 29913212
[TBL] [Abstract][Full Text] [Related]
20. An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient.
Quancard J; Klein T; Fung SY; Renatus M; Hughes N; Israël L; Priatel JJ; Kang S; Blank MA; Viner RI; Blank J; Schlapbach A; Erbel P; Kizhakkedathu J; Villard F; Hersperger R; Turvey SE; Eder J; Bornancin F; Overall CM
Nat Chem Biol; 2019 Mar; 15(3):304-313. PubMed ID: 30692685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
